Rocket Pharma Q1 net loss narrows to $47.6 million; R&D expenses fall to $31.5 million

Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc.

RCKT

0.00
  • Rocket Pharmaceuticals posted a first-quarter net loss of $47.6 million, or $0.42 a share, narrowing from a $61.3 million loss, or $0.56 a share, a year earlier.
  • R&D expense fell 12.26% to $31.5 million, driven by lower manufacturing and development and direct material costs, partially offset by higher clinical trial spending.
  • G&A expense dropped 39.79% to $17.1 million on lower legal and commercial preparation-related costs, partly offset by higher milestone-related expenses.
  • Cash, cash equivalents and investments totaled $144.4 million at March 31, excluding Priority Review Voucher monetization; pro forma cash was about $322.6 million following the $180 million PRV sale, extending expected runway into second-quarter 2028.
  • Dosing restarted in the pivotal Phase 2 RP-A501 Danon disease trial with three additional patients at 3.8 × 1013 GC/kg; first patient dosing in Phase 1 RP-A701 for BAG3-related dilated cardiomyopathy expected in mid-2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rocket Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605071600BIZWIRE_USPR_____20260507_BW193942) on May 07, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.